局部晚期或转移的唾液管癌的性全身疗法:综合性综述
Masafumi Kanno1, Satoshi Kano2, Yoshinori Imamura3
1Division of Otorhinolaryngology-Head and Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Cancer treatment reviews
|July 18, 2025
概括
唾液管癌 (SDC) 治疗以人体表皮生长因子受体2 (HER2) 和雄激素受体 (AR) 状态为指导. 向治疗和化疗提供了基于分子形状的先进SDC的选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 唾液管癌 (SDC) 是一种罕见的,侵略性的癌症,对于不可切除或不可放射治疗的病例,治疗选择有限.
- 对于先进的SDC缺乏标准化的治疗方案,需要个性化治疗策略.
研究的目的:
- 为高级唾液管癌提出基于证据的治疗算法.
- 根据HER2和AR表达来对患者进行分层,以进行量身定制的治疗干预.
主要方法:
- 重大唾液腺癌指导方针的审查.
- 分子形状与临床反应数据的整合.
- 根据HER2和AR表达,将患者分为四组.
主要成果:
- HER2阳性SDC从HER2向治疗中获益 (trastuzumab加 docetaxel);抗体-药物合物在进展中显示有效性.
- 阳性ARSDC显示与雄激素缺乏治疗的活性;HER2-阳性/AR-阳性瘤优先考虑HER2-向治疗.
- 细胞毒性化疗是HER2/AR阴性或耐火病例的选择;免疫检查点抑制剂和下一代测序提供进一步的治疗途径.
结论:
- 一个基于证据的算法整合分子分析 (HER2,AR) 改进了高级SDC的治疗决策.
- 针对性治疗,化疗和新兴策略,如免疫检查点抑制剂和下一代测序,对于优化结果至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K